Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, May 9, 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

May 5, 2014

New two-year data from the Phase 3 ADVANCE clinical trial for peginterferon beta-1a in adults with relapsing forms of multiple sclerosis (RMS) has been presented at the 66th American Academy of Neurology (AAN) annual meeting.

The data indicated that peginterferon beta-1a dosed once every two weeks demonstrated favourable results on relapse rates, magnetic resonance imaging (MRI) findings and disease progression. Over two years, the safety profile of peginterferon beta-1a was consistent with other multiple sclerosis (MS) interferon therapies.

“The two-year data from ADVANCE further establish the efficacy and safety profile of peginterferon beta-1a demonstrated in the first year of the pivotal trial,” said Terry O’Regan, Vice President and Managing Director at Biogen Idec. “If approved, we believe that peginterferon beta-1a dosed once every two weeks will provide MS patients with one of the most significant developments in the interferon class in over a decade.”

ADVANCE was a two-year, Phase 3, placebo-controlled (in year one) study that evaluated the efficacy and safety profile of peginterferon beta-1a administered subcutaneously. The analysis for all primary and secondary efficacy endpoints occurred at the end of year one. After the first year, patients on placebo received peginterferon beta-1a for the duration of the study.

New Analysis of ADVANCE Data Showed Peginterferon Beta-1a Benefits Maintained Over Two Years
A new analysis of data from the second year of ADVANCE presented at AAN demonstrated:
  • The efficacy of peginterferon beta-1a dosed once every two weeks was maintained throughout year two. Relative to year one, the annualised relapse rate (ARR) was further reduced and the number of new or newly-enlarging T2 lesions was numerically lower in year two
  • The safety and tolerability profile of peginterferon beta-1a was consistent between years one and two
These data were presented in a platform presentation on Tuesday, April 29 at 2:00 p.m. EDT:
  • Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005)
More to read, here
……..


To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------
Donate Now Please - Click here
Thank you    
…………………….
.

No comments: